Skizofrenia

Authors

  • Ridho Akbar Syafwan Universitas Andalas

DOI:

https://doi.org/10.55606/klinik.v4i2.4095

Keywords:

antipsychotics, DSM-5, neurotransmitters, psychotic disorders, psychosocial therapy, schizophrenia

Abstract

Schizophrenia is a complex psychiatric disorder, characterized by positive, negative, and significant cognitive impairment, and contributes significantly to global disability. This article is a literature review that comprehensively discusses the epidemiology, etiology, clinical features, diagnosis, and management of schizophrenia. The etiology of schizophrenia involves interactions between genetic, neurobiological, and environmental factors, including dysfunction of neurotransmitters such as dopamine, glutamate, and gaba. Diagnosis can be made based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or the Guidelines for the Classification of Mental Disorder Diagnosis III (PPDGJ III), with an emphasis on the combination of major symptoms and the exclusion of other conditions. Management of Schizophrenia Includes Pharmacological Therapy With First and Second Generation Antipsychotics, As Well As Nonpharmacological Interventions Such As Cognitive-Behavioral Therapy, Social Skills Training, And Family Support. The Social Stigma And Economic Burden That Accompanies It Makes This Disorder A Multidimensional Challenge In The Health System. This Article Emphasizes The Importance Of A Sustained Multidisciplinary Approach To Improve The Prognosis And Quality Of Life Of People With Schizophrenia.

 

 

References

American Psychiatric Association. (2013a). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association.

American Psychiatric Association. (2013b). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association.

Angane, A. (2017). The divine madness: A history of schizophrenia. Annals of Indian Psychiatry, 1(2), 133. https://doi.org/10.4103/AIP.AIP_31_17

Arya, A., Sindhwani, G., & Kadian, R. (2018). NEUROTRANSMITTER AND BRAIN PARTS INVOLVED IN SCHIZOPHRENIA. Asian Journal of Pharmaceutical and Clinical Research, 11(6), 4. https://doi.org/10.22159/ajpcr.2018.v11i6.24557

Ayano, G. (n.d.). Schizophrenia: A Concise Overview of Etiology, Epidemiology Diagnosis and Management: Review of literatures. Retrieved November 4, 2024, from https://www.researchgate.net/publication/318012024_Schizophrenia_A_Concise_Overview_of_Etiology_Epidemiology_Diagnosis_and_Management_Review_of_literatures

Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44(6), 1195. https://doi.org/10.1093/SCHBUL/SBY058

Chong, H. Y., Teoh, S. L., Wu, D. B. C., Kotirum, S., Chiou, C. F., & Chaiyakunapruk, N. (2016). Global economic burden of schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment, 12, 357. https://doi.org/10.2147/NDT.S96649

Correll, C. U., & Schooler, N. R. (2020). Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatric Disease and Treatment, 16, 519. https://doi.org/10.2147/NDT.S225643

Fatani, B. Z., Aldawod, R. A., & Alhawaj, F. A. (2017). Schizophrenia : Etiology, Pathophysiology and Management : A Review. The Egyptian Journal of Hospital Medicine, 69(6), 2640–2646. https://doi.org/10.12816/0042241

Fitrikasari, A., & Kartikasari, L. (2022). Buku Ajar Skizofrenia.

Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2024). Schizophrenia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK539864/

Jain, A., & Mitra, P. (2023). Catatonic Schizophrenia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK563222/

Kesby, J. P., Eyles, D. W., McGrath, J. J., & Scott, J. G. (2018). Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Translational Psychiatry, 8(1), 30. https://doi.org/10.1038/S41398-017-0071-9

Killaspy, H., White, S., Lalvani, N., Berg, R., Thachil, A., Kallumpuram, S., Nasiruddin, O., Wright, C., & Mezey, G. (2014). The impact of psychosis on social inclusion and associated factors. The International Journal of Social Psychiatry, 60(2), 148. https://doi.org/10.1177/0020764012471918

Lu, Y., Pouget, J. G., Andreassen, O. A., Djurovic, S., Esko, T., Hultman, C. M., Metspalu, A., Milani, L., Werge, T., & Sullivan, P. F. (2017). Genetic risk scores and family history as predictors of schizophrenia in Nordic registers. Psychological Medicine, 48(7), 1201. https://doi.org/10.1017/S0033291717002665

Markowicz-Piasecka, M., Kubisiak, M., Asendrych-Wicik, K., Kołodziejczyk, M., Grzelińska, J., Fabijańska, M., & Pietrzak, T. (2024). Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution. Pharmaceutics, 16(1). https://doi.org/10.3390/PHARMACEUTICS16010028

McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023). Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Molecular Psychiatry 2023 28:5, 28(5), 1902–1918. https://doi.org/10.1038/s41380-023-01949-9

Mills, C., Montenegro, C. R., Hart, A., & Demke, E. (2022). The Vulnerability-Stress-Model—Holding Up the Construct of the Faulty Individual in the Light of Challenges to the Medical Model of Mental Distress. Frontiers in Sociology, 7, 833987. https://doi.org/10.3389/FSOC.2022.833987

Rosenbrock, H., Desch, M., & Wunderlich, G. (2023). Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 273(7), 1557–1566. https://doi.org/10.1007/S00406-023-01576-Z

Rupani, K., & Sousa, A. De. (2017). Psychodynamic Theories Of Schizophrenia – Revisited. Indian Journal of Mental Health(IJMH), 4(1), 06. https://doi.org/10.30877/IJMH.4.1.2017.6-15

Substance Abuse and Mental Health Services Administration. (2016). DSM-IV to DSM-5 Schizophrenia Comparison.

Wang, X., Chang, Z., & Wang, R. (2023). Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia. Communications Biology 2023 6:1, 6(1), 1–12. https://doi.org/10.1038/s42003-023-04637-0

Wu, Y., Yao, Y.-G., & Luo, X.-J. (2016). SZDB: A Database for Schizophrenia Genetic Research. Schizophrenia Bulletin, sbw102. https://doi.org/10.1093/schbul/sbw102

Yati, P., Nathania, N. N., Rismawati, A., Lusiana, S., Clara, A. N., Bin Solihin, ny, Fatma Sari, E., Studi Bimbingan Penyuluhan Islam, P., & Dakwah dan Komunikasi, F. (2024). Stigma Masyarakat Terhadap Penderita Skizofrenia. Proceeding Conference on Psychology and Behavioral Sciences, 3, 421–436. https://doi.org/10.61994/CPBS.V3I.149

Yeomans, D., Taylor, M., Currie, A., Whale, R., Ford, K., Fear, C., Hynes, J., Sullivan, G., Moore, B., & Burns, T. (2010). Resolution and remission in schizophrenia: getting well and staying well. Advances in Psychiatric Treatment, 16(2), 86–95. https://doi.org/10.1192/APT.BP.108.006411

Downloads

Published

2025-05-19

How to Cite

Ridho Akbar Syafwan. (2025). Skizofrenia. Jurnal Ilmiah Kedokteran Dan Kesehatan, 4(2), 419–431. https://doi.org/10.55606/klinik.v4i2.4095